DOJ Sides With Sandoz in SCOTUS Case Leftovers Against Amgen

Drug Industry Daily
A A
The U.S. government sided with Sandoz on the residual claims from the biosimilar manufacturer’s Supreme Court case with Amgen — arguing the federal law outlining the biosimilar approval process should preempt state laws on the topic.

To View This Article:

Login

Subscribe To Drug Industry Daily